- Blood Sugar
- Clinical Studies
- Complementary Medicine
- Diabetes and Men
- Erectile Dysfunction
- Food and Nutrition
- Insulin Pumps
- Meters and Test Strips
- Product Recalls
- Type 1
- Type 2
- Weight Loss Surgery
April 15, 2014 (FDA) —
The U.S. Food and Drug Administration today approved Tanzeum (albiglutide) subcutaneous injection to improve glycemic control, along with diet and exercise, in adults with type 2 diabetes.
Type 2 diabetes affects approximately 24 million people and accounts for more than 90 percent of diabetes cases diagnosed in the United States. Over time, high blood sugar levels can increase the risk for serious complications, including heart disease, blindness, a
April 7, 2014 (Bloomberg News) -- Takeda Pharmaceutical Co. (4502) lost the first federal court trial in the U.S. over claims it hid the cancer risks of its Actos diabetes medicine to protect billions of dollars in sales.
The jury in Lafayette, Louisiana, today awarded $1.5 million in compensatory damages and will consider a request for punitive damages.
Takeda, Asia's largest drugmaker, faces the Actos claims after it scrapped development o
July 23, 2013 (FDA) — The U.S. Food and Drug Administration is taking action to remove from the market illegal products, including some labeled as dietary supplements, that claim to mitigate, treat, cure or prevent diabetes and related complications. The agency recently issued letters warning 15 companies that the sale of their illegally marketed diabetes products violates federal law. The letters were sent to foreign and domestic companies whose products were sold online and in retail st
June 14, 2013 (Newswise) — The new weight loss drug lorcaserin (Belviq) appears to improve blood sugar control in nondiabetic, overweight individuals, independent of the amount of weight they lose, a new study finds. The results will be presented Saturday at The Endocrine Society's 95th Annual Meeting in San Francisc
May 16, 2013 (Newswise) — A clinical trial at the University of Chicago Medicine aims to find new ways of preventing type 2 diabetes or slow its progression by treating participants with medications normally used for people who have had full-blown diabetes for at least one year. The trial will enroll individuals who are pr